Imaging Partnership Has Aimed to Improve Obesity Research
New clinical imaging collaborations could provide more precise data on how weight loss drugs affect fat versus muscle.
Updated on Sept. 28, 2026 in Weight Loss
Live Poll
Do you believe partnerships between imaging companies improve clinical trial outcomes for new medical therapies?
Image Analysis Group and Resonance Health have launched a partnership to integrate advanced body-composition imaging into clinical trials. This effort aims to help researchers better distinguish between reductions in fat and changes in lean muscle mass during obesity and metabolic disease studies.
Why it matters
Distinguishing between adipose tissue loss and muscle wasting is critical for understanding the safety and efficacy of modern obesity treatments. By combining multiple imaging modalities, developers can gain a more nuanced view of how metabolic interventions alter body composition.
The DYNAMIKA platform currently supports more than 700 clinical trials globally. The partnership plans to implement a body-composition panel that utilizes both DXA and quantitative MRI, though specific validation data for this combined approach remains in development.
The players
Image Analysis Group
A medical imaging provider specializing in centralized analysis and workflows for clinical trials.
Resonance Health
A health technology company that develops quantitative imaging analysis software for liver and body composition assessment.
The details
The collaboration integrates Resonance Health’s quantitative MRI capabilities, including the HepaFatScan for liver fat assessment, with Image Analysis Group’s existing DXA and muscle imaging workflows. By layering these technologies within the DYNAMIKA platform, the companies intend to create a comprehensive panel for clinical development. This allows trial sponsors to simultaneously track fat distribution and muscle mass retention across global study sites.
Timeline
September 28, 2026: The partnership was publicly announced.
Health Landscape
The partnership expands the diagnostic capabilities of the DYNAMIKA platform, which currently serves as a central hub for over 700 active global clinical trials. This integration marks a shift toward higher-resolution body-composition data as a standard requirement in metabolic drug development.
This development focuses on the tools used in clinical research rather than direct clinical care. While this may improve the quality of data for future obesity treatments, patients should continue discussing the risks and benefits of specific weight management drugs directly with their physician.
The takeaway
Advancements in multi-modal imaging like this help ensure that clinical trials provide a complete picture of how treatments change body composition. When evaluating new metabolic therapies, ask your doctor about the data available regarding muscle preservation and long-term health outcomes.
Further reading
For more on the latest research developments in this field, visit our Weight Loss section.
Source note: This article includes information reported by Scientist Live.
Live Poll
Do you believe partnerships between imaging companies improve clinical trial outcomes for new medical therapies?
